Licensed Practical Nurse in Parksville, NY Accepting Medicare
4 Licensed Practical Nurse nurses found. Showing 1 - 4
 Ms. Tara Louise Knack-moreno, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1032 Cooley Road, Parksville, NY 12768 Phone: 845-807-1877 |
Dianne T Cunningham, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 437 Parksville Road, Parksville, NY 12768 Phone: 845-292-3296 |
Alice J Bose, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 437 Parksville Rd, Parksville, NY 12768 Phone: 845-292-3296 |
Ms. Carol Jean Fearby, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2012 Cooley Mountain Rd, Parksville, NY 12768 Phone: 845-292-7985 |
News Archive
GW Pharmaceuticals receives U.S. patent for treating glioma
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.
Largest hepatitis-C U.S. study defines optimal therapy
Final results of the WIN-R trial,[1] the largest hepatitis C study conducted in U.S. patients, showed that weight-based REBETOL (ribavirin, USP) in combination therapy with PEG-INTRON (peginterferon alfa-2b) achieved significantly higher rates of sustained virologic response (SVR)[2] and lower rates of relapse compared to the combination therapy using a flat dose of ribavirin.
New understandings of diagnosis, treatment and prevention of COPD
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has released new standards for the diagnosis, management and prevention of chronic obstructive pulmonary disease (COPD).
Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform
Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.
› Verified 9 days ago